1,720,984 research outputs found
Transcription factor Runx2 is induced in vascular aging and may promote age-related arterial stiffness
No full textTranscription factor Runx2 is induced in vascular aging and may promote age-related arterial stiffness
No full textMicroRNA miR-29b is a mediator of aortic stiffness and hypertension in a murine model of diabetes mellitus type 2
No full textMicroRNA miR-29b is a mediator of aortic stiffness and hypertension in a murine model of diabetes mellitus type 2
No full textAbstract 678: microRNA 146a Reduces Activity of Matrix-Metalloproteinases in the Context of Arterial Stiffness
No full textUnresolved Issues in RNA Therapeutics in Vascular Diseases With a Focus on Aneurysm Disease
No full textNew technologies have greatly shaped the scientific and medical landscape within the last years. The unprecedented expansion of data and information on RNA biology has led to the discovery of new RNA classes with unique functions and unexpected modifications. Today, the biggest challenge is to transfer the large number of findings in basic RNA biology into corresponding clinical RNA-based therapeutics. Lately, this research begins to yield positive outcomes. RNA drugs advance to the final phases of clinical trials or even receive FDA approval. Furthermore, the introduction of the RNA-guided gene-editing technology CRISPR and advances in the delivery of messenger RNAs have triggered a major progression in the field of RNA-therapeutics. Especially short interfering RNAs and antisense oligonucleotides are promising examples for novel categories of therapeutics. However, several issues need to be addressed including intracellular delivery, toxicity, and immune responses before utilizing RNAs in a clinical setting. In this review, we provide an overview on opportunities and challenges for clinical translation of RNA-based therapeutics, with an emphasis on advances in novel delivery technologies and abdominal aortic aneurysm disease where non-coding RNAs have been shown to play a crucial regulatory role
NON-CODING RNAS COMPREHENSIVELY COUNTERACT ADVERSE ARTERIAL REMODELING AND STIFFENING IN TYPE 2 DIABETES
No full textGranular Media Calcinosis in the Aortic Walls of Patients With Bicuspid and Tricuspid Aortic Valves
No full textBackground. Bicuspid aortic valve (BAV), the most frequent congenital cardiac abnormality, is associated with a higher risk for ascending aortic aneurysms and aorta-related complications (ie, dissection and rupture). The aim of this study was to quantify granular media calcinosis (GMC) in the ascending aortic wall of patients with BAV. Methods. We analyzed samples of the ascending aorta from patients with BAV (n = 54) and patients with tricuspid aortic valve (TAV) (n = 33) who underwent aortic repair, regarding medial thickness and diameter expansion. Additionally, the convexity and concavity of the samples were stained for GMC and elastin fragmentation. Results. The quantitative analysis revealed a significantly higher extent of GMC in patients with BAV at the aortic convexity and concavity compared with patients with TAV, independent of aortic diameter. Additionally, GMC increased with enlargement of the aortic diameter in patients with BAV. Furthermore, we found a significantly reduced total medial thickness in patients with BAV compared with patients with TAV. Conclusions. Our findings highlight GMC as a prominent feature of bicuspid aortopathy. (C) 2017 by The Society of Thoracic Surgeon
NON-CODING RNAS COMPREHENSIVELY COUNTERACT ADVERSE ARTERIAL REMODELING AND STIFFENING IN TYPE 2 DIABETES
No full text- …
